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Abstract
Backgrounds: Malaria is a major public health problem in the tropical and subtropical
areas of the world, including Africa. Most cases of malaria in Africa are caused by
Plasmodium falciparum.
Objectives: This study was aimed to assess the hematological changes in patient with
falciparum malaria and to estimate the incidence of leucopenia, thrombocytopenia,
and its response to anti-malaria therapy, and to correlate the association of the
hematological changes with P. falciparum-positive (study group) and P. falciparum-
negative (control group).
Methodology: A total of 453 participants (353 cases and 100 as control group) were
enrolled in this study, all of them were randomly selected from Elnihoud Teaching
Hospital, Elnihoud Locality, West Kordufan State, Sudan. Questionnaire was filled by
every participant and thick and thin blood films for malaria were prepared and stained
by giemsa stain and the CBC was done by sysmex automated hematological analyzer.
Results: Thrombocytopenia, leucopenia, microcytic hypochromic red blood cells and
relative lymphocytosis have significant association with falciparum malaria with P-
values 0.008, 0.001, 0.008, and 0.004, respectively.
Conclusion: Patients with thrombocytopenia and/or leucopenia with malaria should
receive anti-malaria therapy and follow-up by CBC, and shouldn’t be hurried for a
bone marrow examination.
Keywords: falciparum malaria, thrombocytopenia, leucopenia, relative lymphocytosis
How to cite this article: Abdelnassir M. Ahamed, Hafiz Ahmed Hobiel, Gad Allah Modawe, and Mohammed Saeed Elsammani (2019) “Hematological
Changes in Sudanese Patients with Falciparum Malaria Attending Elnihoud Teaching Hospital,” Sudan Journal of Medical Sciences, vol. 14, issue





Received 15 January 2019
Accepted 26 March 2019
Published 31 March 2019
Production and Hosting by
Knowledge E
Abdelnassir M. Ahamed
et al. This article is distributed
under the terms of the
Creative Commons
Attribution License, which
permits unrestricted use and
redistribution provided that
the original author and
source are credited.
Editor-in-Chief:
Prof. Mohammad A. M. Ibnouf
Sudan Journal of Medical Sciences Abdelnassir M. Ahamed et al
1. Introduction
Malaria is a major public health problem in the tropical and subtropical parts of the world
[1]. It is one of the most common dangerous protozoan disease in which most cases in
Africa are caused by P. falciparum, with a relatively small proportion attributable to P.
malariae or P. ovale, while P. vivax is known to occur in only some areas of the region
[2]. An estimated 219 million cases of malaria occurred worldwide in 2017 compared
with 239 million cases in 2010 and 217 million cases in 2016. The WHO African region
still bears the largest burden of malaria morbidity, with 200 million cases (92%) in 2017,
followed by the WHO South-East Asia Region (5%) and the WHO Eastern Mediterranean
Region (2%) [3].
The clinical manifestation of falciparum malaria varies from mild acute febrile illness
to life-threatening severe systemic complications involving one or more organ systems
[4]. It causes significant hematological changes ranging from hemolytic anemia (Hb <
10 g/dl.), defective erythropoiesis, and reticulocyte production, leukocytosis (WBC > 11
X 103/Microliter), leukocytopenia (WBC < 4 X103/Microliter), thrombocytopenia (TCP)
platelets count less than 150 x103/Microliter, platelet dysfunction in severe malaria,
and disseminated intravascular coagulation (DIC) (5). Severe TCP is frequently noticed
with P. falciparum Malaria [5]. TCP during malarial infection may appear even before
fever, anemia, and splenomegaly become manifest [6]. During early stages of malaria,
platelet agglutination as a result of endothelial cell activation and release of activated
von Willebrand factor occur which may cause thrombocytopenia [7]. Direct invasion of
platelets by malarial parasites may occur. Thrombocytopenia in malaria is usually mild
and treated by eradication of malaria parasite [8]. Thrombocytopenia is an early and
consistent feature of malaria, but its pathogenesis remains incompletely understood
[9]. The causes of thrombocytopenia in falciparum malaria are increased platelet con-
sumption as evidenced by shortened survival of platelets and the finding of increased
megakaryocytes in patient’s bone marrow and elevated plasma thrombopoietin levels
[10], and systemic microvascular sequestration and endothelial activation may play a
pathophysiological role, a hypothesis supported by the observation that the radio-
labelled platelets of patients with falciparum malaria are diffusely sequestered rather
than pooling in the liver or spleen [11]. Population studies have shown an association
between thrombocytopenia and outcome, and a recent study from India proposed that
thrombocytopenia should be added to the World Health Organization (WHO) criteria for
the definition of severe malaria [12]. This study was aimed to assess the hematological
changes in patients with falciparum malaria.
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2. Materials and Methods
This study was an analytical cross-sectional study, carried out in Elnihoud Teaching
Hospital, Elnihoud Locality, West Kordufan State, Sudan, from April 2015 to April 2016.
Elnihoud Teaching Hospital is tertiary referring hospital receiving approximately about
15,000 patients suffering from malaria annually. A total of 453 participants (353 cases
and 100 as control group) were enrolled in this study, all of themwere randomly selected.
Participants with positive blood film for malaria were taken as cases group, and febrile
patients with a negative result for malaria were taken as control group, any patient with
hematological disorders was excluded. The institutional research and ethics approval
was obtained before the commencement of the study. All participants spoke sufficient
Arabic to provide informed consent. Questionnaires were filled, blood samples were
obtained for the detection of malaria using giemsa-stained thick- and thin blood films
and stander diagnostic (SD) ICT for malaria antibodies. Full blood count was done for the
patients with abnormal blood count twoweeks after completing the anti-malaria therapy;
the complete blood count (CBC) was analyzed by automated hematological analyzer
(sysmex XP-300); also the peripheral blood film was stained by Leishman’s stain and
screened by an expert hematologist. The data were analyzed by SPSS program version
20.
3. Results
The distribution of the ages of the study participants were between 4 months and 75
years with the mean of 29 +/– 3.4 years. Of the total participants, 216 (88.5%) were rural
while 28 (11.5%) were urban. The study results show that the incidence of pancytopenia
among study group was 6 out of 353 (1.7%) (Table 1).
The incidences of anemia, leucopenia, and thrombocytopenia among the study group
were: 77 out of 353 (21.8%), 22 out of 352 (6.3%), and 75 out of 353 (21.3%), respectively.
Whereas, on the other hand, the incidences of microcytic hypochromic red blood cells
and relative lymphocytosis (the absolute lymphocyte count is normal but it is more than
neutrophil count) among study group were 140 out of 353 (39.7%) and 51 out of 267
(19.1%), respectively. There was a statistically significant positive association between
P. falciparum malaria and leucopenia, relative lymphocytosis, thrombocytopenia and
microcytic hypochromic red blood cells with P-values 0.001, 0.004, 0.008, and 0.008,
respectively (Table 2). Two weeks’ follow-up after completing the treatment, 90.7% of
thrombocytopenic and 90.9% of thrombocytosis patients showed normal platelet count.
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For WBCs, 90.9% of leukopenia and 86.5% of leukocytosis patients revealed normal
value (Table 3).
Table 1: Characteristics and description of the study groups.
Characteristic Patient Control Total P-value
Age
Under 5 years 37(12%) 33(24.7%) 70(17.3%)
5 to 14 years 46(14.9%) 12(12.6%) 58(14.4%)
15 to 50 years 164(53.1%) 34(35.8%) 198(49%) < 0.001
Above 50 years 62(20.1%) 16(16.8%) 78(19.3%)
Total 309(100%) 95(100%) 404(100%)
Sex
Male 188(76.7%) 57(23.3%) 245(54.2%)
Female 165(79.7%) 42(20.3%) 207(45.8%) 0.128
Total 353 (100%) 99(100%) 452(100%)
Residence Area
Rural 216(88.5%) 68(81.9%) 284(86.9%)
Urban 28(11.5%) 15(18.1%) 43(13.1%) 0.135
Total 244(100%) 83(100%) 327(100%)
Incidence of
pancytopenia
Present 6(1.7%) 0(0.00%) 6(1.3%)
Absent 347(98.3%) 100(100%) 347(98.7%) 0.346
Total 353 (100%) 100 (100%) 453 (100%)
4. Discussion
This study sets out to describe the hematological changes in P. falciparum patients in
Elnihoud Teaching Hospital, the study results revealed that there was a significant pos-
itive association between thrombocytopenia and P. falciparum malaria (P-value 0.008),
which is consistent with [7, 13, 14], who stated that the most common complications
of falciparum malaria is thrombocytopenia and platelet dysfunction. The thrombocy-
topenia is usually not associated with bleeding even in patients with very severe form
(platelets less 10 x 103/microliter), and there was a complete recovery after treatment,
so thrombocytopenia is a significant indicator for malaria, especially in correlation with
typical fever and hypotension. Also, the study shows a significant positive association
between leucopenia and P. falciparum malaria (P-value 0.001), which is in agreement
with Ladhani et al. [15], who reported that leucopenia and thrombocytopenia occurred
with P. falciparum malaria, but these were not associated with death. The leucopenia
occurred most probably due to a bone marrow suppression, resulting from cytokines
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Table 2: Comparison of hematological parameters of the study groups.
Characteristic Patient Control Total P-value
Hb
Normal 275(77.9%) 85(85%) 360(79.5%)
Anemia 77(21.8) 15(15%) 92(20.3%)
Polycythemia 1(0.3%) 0(0%) 1(0.2%) 0.278
Total 353(100%) 100 (100%) 453(100%)
TWBC
Normal 293(83.2%) 69(69%) 362(80.1%)
Leucopenia 22(6.3%) 5(5%) 27(6%) < 0.001
Leukocytosis 37(10.5) 26(26%) 63(13.9%)
Total 352(100%) 100(100%) 452(100%)
PLT
Normal 267(75.6%) 79(79%) 346(76.4%)
Thrombocytopenia 75(21.3%) 12(12%) 87(19.2%)
Thrombocytosis 11(3.1%) 9(9%) 20(4.4%) 0.008
Total 353 (100%) 100 (100%) 453 (100%)
MCV
Normal 210(59.5%) 42(42%) 252(55.6%)
Microcytic 140(39.7%) 57(57%) 197(43.5%) 0.008
Macrocytic 3(0.8%) 1(1%) 4(0.9%)
Total 353 (100%) 100 (100%) 453 (100%)
Relative lymphocytosis
Yes 51(19.1%) 1(2.3%) 52(16.8%) 0.004
No 216(80.9%) 42(97.7%) 258(83.2%)
Total 267(100%) 43 (100%) 310 (100%)










Leucopenia 22(37.3%) 2 (28.6%) 20 (38.5%)
Leukocytosis 37(62.7%) 5 (71.4%) 32 (61.5%) 0.001
Total 59 (100%) 7 (100%) 52 (100%)
Thrombocytopenia 75 (87.2%) 7 (87.5%) 68 (87.2%)
Thrombocytosis 11 (12.8%) 1 (12.5%) 10 (12.8%) 0.001
Total 86 (100%) 8 (100%) 78 (100%)
production and/or folate deficiency when associated with pancytopenia. There was
a significant positive association between microcytic hypochromic red blood cell and
P. falciparum malaria (P-value 0.008) as it is stated by WHO [8] which reported the
same point. Microcytic hypochromic red cells might due to either hepcidin production
or loss of appetite and poor diet especially in childhood period. The study revealed
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a significant positive association between relative lymphocytosis and P. falciparum
malaria (P-value 0.004), same result reported by Ladhani et al. [15]; this might be a part
of the bone marrow failure which is associated with neutropenia because neutrophil
has short half-life compared with lymphocytes and its deficiency appears early. There
was no significant association with anemia and so pancytopenia because hemoglobin
can take time to show a significant drop.
Two weeks after completing the treatment, patients with abnormal blood counts
showed normal values that indicates that these patients should receive anti-malaria
therapy irrespective of malaria-parasite results.
5. Conclusion
The study findings demonstrate that P. falciparummalaria is one of the common causes
of hematological changes. The results showed that there was a statistically significant
positive association between P. falciparum malaria and each of leucopenia, relative
lymphocytosis, thrombocytopenia, and microcytic hypochromic red blood cells.
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